替莫唑胺治疗复发性恶性脑胶质瘤疗效

Efficacy of temozolomide in treating recurrent malignant glioma

目的评价替莫唑胺治疗复发性脑恶性胶质瘤的疗效及安全性。方法 38例复发的恶性胶质瘤患者给予单药替莫唑胺100-200mg/m2,连续口服5d,28d为一周期。所有患者至少接受两个疗程治疗。替莫唑胺化疗后以头颅MRI判断疗效,并记录相关治疗反应。结果中位随访时间8.5个月。8例患者的肿瘤明显缩小,PR率为21.05%;13例患者肿瘤稳定,SD率为34.24%。中位无进展生存期为5.4个月;17例(44.74%)患者无进展生存期超过6个月;1年生存率23.68%(9/38)。替莫唑胺主要不良反应为恶心、呕吐、乏力和骨髓抑制等。结论口服替莫唑胺对恶性复发性胶质瘤患者安全有效。

Objective To evaluate the efficacy and adverse effects of temozolomide in the treatment of recurrent glioma.Methods Thirty-eight patients with recurrent glioma were treated with temozolomide in a dose of 100-200 mg/m2 once a day for 5 days.A treatment cycle was 28 days and each patient received at least two cycles of treatment.The efficacy was evaluated by MRI examination after chemotherapy.Results Median follow-up time was 8.5 months.The partial response rate was 21.05%（8/38）,stable disease rate was 34.24%（13/38）.The median time for disease progression-free survival was 5.4 months.Seventeen（44.74%） patients were progression-free survival more than 6 months.One-year survival rate was 23.68%.There were no severe temozolomide-related toxicities.The major adverse effects of temozolomide were nausea,vomiting,baldness,acratia and bone marrow depression.Conclusion Treating recurrent gliomas with temozolomide is effective and safe with less adverse effects.